Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Vistar Eye Center

Neither a doctor nor a teaching hospital

Research payments

$450,034

167 payments

Through program year 2025, Vistar Eye Center is reported as receiving $450,034 in research payments, across 167 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $14,730 9
2024 Research $39,847 11
2023 Research $33,460 12
2022 Research $41,274 13
2021 Research $60,215 14
2020 Research $112,116 56
2019 Research $148,393 52

Breakdown

Who paid Research payments · program years 2019–2025
  1. Glaukos Corporation $404,356 107 payments
  2. AbbVie, Inc. $23,314 4 payments
  3. Allergan Inc. $12,365 55 payments
  4. Astellas Pharma Global Development $10,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5 $98,266 13 payments
  2. Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5% $98,005 11 payments
  3. Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5 $60,215 14 payments
  4. Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension $52,612 19 payments
  5. A Prospective, Multicenter Clinical Investigation of the Glaukos Trabecular Micro-Bypass System, Model iS3, in Subjects with Refractory Glaucoma $30,663 9 payments
  6. Long-term Safety and Efficacy Extension Trial of Bimatoprost SR $21,566 2 payments
  7. A Prospective, Randomized, Single-Masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos Suprachoroidal Stent Model G3 In Conjunction With Cataract Surgery $14,879 11 payments
  8. Prospective, Randomized Phase 3 Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, USP, 0.5% $13,380 9 payments
  9. A Phase 3 Multicenter, Randomized, Double Masked, Sham-Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients with Geographic Atropy Secondary to Age-Related Macular Degeneration $10,000 1 payment
  10. A Prospective, Multicenter Clinical Investigation of the Glaukos Trabecular Micro-Bypass System, Model iS3, in Subjects with Refractory Glaucoma $6,330 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record